High density lipoprotein landmark trials: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) No edit summary |
Rim Halaby (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{High density lipoprotein}} | {{High density lipoprotein}} | ||
{{CMG | {{CMG}} | ||
==Reconstituted HDL Infusion== | ==Reconstituted HDL Infusion== |
Revision as of 14:54, 19 September 2013
High Density Lipoprotein Microchapters |
Diagnosis |
---|
Treatment |
Clinical Trials |
Case Studies |
High density lipoprotein landmark trials On the Web |
American Roentgen Ray Society Images of High density lipoprotein landmark trials |
Risk calculators and risk factors for High density lipoprotein landmark trials |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Reconstituted HDL Infusion
CHI-SQUARE Study |
CSL-112 Trial - Phase 1 |
CSL-112 Trial - Phase 2a |
ERASE Trial |
Infusion of Apo A-1 Milano |
CETP Inhibitors
ACCELERATE Trial |
DAL-Outcomes Trial |
DEFINE Trial |
ILLUMINATE Trial |
ILLUSTRATE Trial |
REVEAL Trial |
Niacin
AIM-HIGH Trial |
ARBITER 2 Trial |
ARBITER 3 Trial |
ARBITER 6-HALTS Trial |
CLAS Trial |
HATS Trial |
Oxford Niaspan Study |
Fibrate
VA-HIT Trial |
BECAIT Trial |
BIP Trial |
Statin
ASTEROID Trial |
SATURN Trial |
4S Trial |
CORONA Trial |
Multiple Lipid Lowering Drugs
HARP Study |
AFREGS Trial |